ReviewTargeted oncology2016
Dinutuximab: A Review in High-Risk Neuroblastoma.
Review in Targeted oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.The Cochrane database of systematic reviews · 2019Pooled it
- Therapeutic Antibodies in Medicine.Molecules (Basel, Switzerland) · 2023Review
- Safety and efficacy of dinutuximab in the treatment of neuroblastoma: A review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Review
- Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma.Targeted oncology · 2023Review
- GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype.Cancers · 2022Article
- Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy.Molecular diagnosis & therapy · 2021Review
- Development of a dinutuximab delivery system using silk foams for GD2 targeted neuroblastoma cell death.Journal of biomedical materials research. Part A · 2021Article
- Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model.Cancer medicine · 2020Article
- Repurposing a psychoactive drug for children with cancer: p27Oncogenesis · 2020Article
- Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma.Frontiers in cell and developmental biology · 2020Review
- The Current Status and Future Potential of Theranostics to Diagnose and Treat Childhood Cancer.Frontiers in oncology · 2020Review
- Immunotherapies for pediatric cancer: current landscape and future perspectives.Cancer metastasis reviews · 2019Review
- Challenges and Opportunities for Childhood Cancer Drug Development.Pharmacological reviews · 2019Review
- RDM1 promotes neuroblastoma growth through the RAS-Raf-MEK-ERK pathway.FEBS open bio · 2019Article
- Ganglioside GD3 synthase (GD3S), a novel cancer drug target.Acta pharmaceutica Sinica. B · 2018Review
- S-trityl-L-cysteine, a novel Eg5 inhibitor, is a potent chemotherapeutic strategy in neuroblastoma.Oncology letters · 2018Article
- Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.Immunology and cell biology · 2017Review
- New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Frontiers in immunology · 2017Review
- Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?Frontiers in immunology · 2017Review
- [Clinical features and outcomes of neuroblastoma patients aged above 5 years].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dinutuximab (ch14.18; Unituxin™) is a chimeric human-mouse monoclonal antibody that binds to the glycolipid antigen disialoganglioside, which is highly expressed on the surface of neuroblastoma cells. This intravenous drug is approved in the EU and USA as combination therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2 and isotretinoin for the postconsolidation treatment of patients with high-risk neuroblastoma. In a multinational, phase III study in this patient population, event-free survival (EFS) benefits with the dinutuximab-containing regimen versus isotretinoin alone were observed at the time of the primary (p = 0.0115) and confirmatory (p = 0.0330) efficacy analyses, although the observed p-value for the between-group difference in EFS for the primary efficacy analysis did not cross the prespecified boundary for statistical significance (p < 0.0108). Significant and sustained (5 years) overall survival benefits were seen with the dinutuximab-containing regimen versus isotretinoin alone. Despite pretreatment with analgesics, antihistamines and antipyretics, serious adverse reactions have been reported with the dinutuximab-containing regimen, with infusion reactions and neuropathy prompting the US FDA to issue boxed warnings. Dinutuximab administered in combination with GM-CSF, IL-2 and isotretinoin represents an important advance in the postconsolidation treatment of patients with high-risk neuroblastoma, with its benefits outweighing its risks in a patient population with a poor prognosis and limited therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.